Fda Approvals In Cscc Nsclc And Myeloma Breakthrough Designation In Prostate Cancer And More Onclive Mp3 & Mp4 Download

5:55

fda approval in myeloma, breakthrough designations in rcc and aplastic anemia, and more

10:55

fda approval in myeloma, label update in her2 breast cancer, and more

10:08

fda approvals in myeloma and attp, priority review designations in rcc and hnscc, and more

12:17

fda approvals in breast cancer and prostate cancer, priority review in breast cancer, and more

10:49

fda approvals in melanoma and breast cancer, and priority reviews in prostate cancer and more

13:01

fda approvals in urothelial cancer and prostate cancer, priority review in crc, and more

9:02

fda approval in sarcoma, priority reviews in mcrpc and myeloma, and more

10:49

fda approvals in myeloma, nets, and of a biosimilar, priority review in ovarian cancer, and more

10:23

fda approvals in hematologic malignancies, sbla accepted in multiple myeloma, and more

9:24

fda approvals in myeloma and head and neck cancer, and findings across several tumor types

6:59

fda approval in nsclc, priority review in bladder cancer, mbcc highlights, and more

6:48

fda approval in prostate cancer, phase iii data in breast cancer, and more

13:36

fda approval in prostate cancer, nda submitted in cll and follicular lymphoma, and more

9:41

fda approvals in follicular lymphoma and prostate cancer, biosimilar is granted approval, and more

10:20

fda approvals in myeloma and thyroid cancer, priority review and nda in nsclc, and more

7:28

breakthrough designation in all, hifu fda approval, breast cancer screening update, and more

12:53

fda approval in sclc, partial hold in myeloma trials, nccn guideline update in crc, and more

6:27

fda approval in myeloma, priority review in all, and 2017 gu cancers symposium highlights

0:31

fda approvals in cscc, nsclc, and myeloma, breakthrough designation in prostate cancer, and more

Download video MP4

Download video MP3

Similar videos

fda approval in myeloma, breakthrough designations in rcc and aplastic anemia, and more

fda approval in myeloma, label update in her2 breast cancer, and more

fda approvals in myeloma and attp, priority review designations in rcc and hnscc, and more

fda approvals in breast cancer and prostate cancer, priority review in breast cancer, and more

fda approvals in melanoma and breast cancer, and priority reviews in prostate cancer and more

fda approvals in urothelial cancer and prostate cancer, priority review in crc, and more

fda approval in sarcoma, priority reviews in mcrpc and myeloma, and more

fda approvals in myeloma, nets, and of a biosimilar, priority review in ovarian cancer, and more

fda approvals in hematologic malignancies, sbla accepted in multiple myeloma, and more

fda approvals in myeloma and head and neck cancer, and findings across several tumor types

fda approval in nsclc, priority review in bladder cancer, mbcc highlights, and more

fda approval in prostate cancer, phase iii data in breast cancer, and more

fda approval in prostate cancer, nda submitted in cll and follicular lymphoma, and more

fda approvals in follicular lymphoma and prostate cancer, biosimilar is granted approval, and more

fda approvals in myeloma and thyroid cancer, priority review and nda in nsclc, and more

breakthrough designation in all, hifu fda approval, breast cancer screening update, and more

fda approval in sclc, partial hold in myeloma trials, nccn guideline update in crc, and more

fda approval in myeloma, priority review in all, and 2017 gu cancers symposium highlights

preview: fda approvals in nsclc and soft tissue sarcoma, priority review in bladder cancer, and more